Novo Nordisk A/S reported DKK18.44B in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Bausch Health Companies USD 1.83B 526M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novo Nordisk DKK 21.13B 17.81B Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026